2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Melanoma
250
Carcinoma, Non-Small-Cell Lung
86
Carcinoma, Renal Cell
62
Neoplasm Metastasis
53
Neoplasms
51
Prostatic Neoplasms
35
Lung Neoplasms
32
Uveal Melanoma
29
Pancreatic Neoplasms
28
Carcinoma, Hepatocellular
25
Brain Neoplasms
24
Colorectal Neoplasms
23
Sarcoma
22
Breast Neoplasms
20
Squamous Cell Carcinoma of Head and Neck
18
Small Cell Lung Carcinoma
18
Kidney Neoplasms
18
Skin Neoplasms
17
Diabetes Mellitus, Insulin-Dependent, 12
17
Carcinoma, Transitional Cell
17
Ovarian Neoplasms
15
Urinary Bladder Neoplasms
14
Triple Negative Breast Neoplasms
14
Mesothelioma
13
Glioblastoma
13
Uterine Cervical Neoplasms
12
Recurrence
12
Multiple Myeloma
11
Lymphoma
11
Clear-cell metastatic renal cell carcinoma
11
Interventions
Blood Specimen Collection
9
Surveys and Questionnaires
6
Magnetic Resonance Spectroscopy
6
Dexamethasone
6
Cyclophosphamide
6
Prednisone
5
Mammography
5
Colonoscopy
5
Biopsy
5
Positron Emission Tomography Computed Tomography
4
Magnetic Resonance Imaging
4
Lenalidomide
4
Biopsy, Fine-Needle
4
pembrolizumab
3
Tomography, X-Ray Computed
3
Surgical Procedures, Operative
3
Melphalan
3
Liquid Biopsy
3
Interviews as Topic
3
Exercise
3
Diagnostic Tests, Routine
3
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
3
weifuchun
2
obinutuzumab
2
fluciclovine F-18
2
daratumumab
2
carfilzomib
2
Urination
2
Preoperative Exercise
2
Positron-Emission Tomography
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease
×
Ipilimumab
×
Clear all
NCT04855929
2024-11-08
ANV419-001
Anaveon AG
Phase 1
Completed
55 enrolled